Office of the IRB

Office of the IRB

Office of the IRB
AAHRPP_Full_Color_150.gifThe UAB Institutional Review Board for Human Use (IRB) is a committee established under federal regulations for the protection of human subjects in research (45 CFR 46). Its purpose is to help protect the rights and welfare of human participants in research conducted under the auspices of the University of Alabama at Birmingham.
 
The guiding ethical principles of the IRB— respect for persons, beneficence and justice—are embodied in the “Belmont Report”: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, April 18, 1979).
 
University policy requires that all research involving human subjects be reviewed and approved by the UAB IRB before the research begins. This requirement applies to all human subjects research conducted by faculty, staff, and students, on- and off-campus, regardless of funding.
 
Research involving human subjects includes the collection of data about or from human subjects and the use of existing data or specimens. Any changes to an IRB-approved project must be reviewed and approved by the IRB before they can be implemented. Continuing review is also required at regular intervals for protocols reviewed by the convened IRB and through expedited procedures.
 
The UAB IRB requires Principal Investigators and all other research team members to complete and document appropriate training in the protection of human subjects. Additionally, the IRB monitors ongoing research for adherence to applicable regulations, policies, and procedures.
 
More information about the IRB and its role in the UAB Human Research Protection Program can be found on this website or by contacting the staff in the Office of the IRB.​

IRB News and Announcements

  • Changes to Consent Form May 2014

    ​The following are changes to the Sample Consent Form, version 05/29/14

    • Font has been changed to Calibri to comply with Institutional style guidelines.
    • Header:  The header has been updated to include Sponsor Protocol No., when applicable.
    • Risks and Discomforts:  Clarification to instructions in Randomization section and revisions to the example paragraph have been made.
    • Confidentiality:  
      • Change in language regarding publishing results of research
      • Updated Billing Compliance language
      • Addition of clinical trials indicator in medical records
    • Voluntary Participation and Withdrawal:  Instructions have been updated.
    • Cost of Participation:  Addition of sample language regarding Category B medical devices.
    • Signatures:  Several changes in the guidance.
    • HIPAA Authorization Form:  Revision to consent cancellation language.

    Click here for a more detailed summary of the changes.

    The sample consent form is available online by clicking this link.

    Posted by Office of the Institutional Review Board for Human Use | 06/04/14
  • FDA 1572 Updated

    Version date 07/2013, available at the following link:
    Posted by Office of the Institutional Review Board for Human Use | 01/01/13